Interim ResultStrong profit growth from operations, up 36% to...

Interim Result
Strong profit growth from operations, up 36% to $349 million
CSL Limited today announced a profit after tax of $349 million for the six months ended
31 December 2007, up 36% when compared to the six months ended 31 December 2006.
This included an adverse foreign currency impact of $28m, when compared with the prior
comparable period (PCP).
HIGHLIGHTS
Financial
• Total revenue of $1.9 billion, up 20% when compared to the six months ended 31
December 2006, or up 29% when adjusting for currency movements:
• GARDASIL® royalty of $81m;
• GARDASIL® – Australian sales $143m;
• Net profit after tax grew 36% to $349m;
• Includes an adverse foreign currency impact of $28m when compared with PCP;
• Net operating cash flow up 57% to $293m;
• Earnings per share of 63.4 cents, up 35%1;
• Interim dividend up 41%1 to 23 cents per share, unfranked, payable on 14 April 2008.
Operational
• Robust global demand for plasma therapies continues;
• Excellent European rollout of GARDASIL® by sanofi pasteur-MSD, a joint venture of
Merck and Co., Inc (Merck) and sanofi aventis;
• Encouraging uptake of GARDASIL® in Australia;
• Privigen® (10% liquid intravenous immunoglobulin) approved July 2007 by US FDA;
• launched in the USA during February 2008;
• Influenza vaccine approved by US FDA;
• Rheumatoid arthritis antibody licensed to MedImmune / AstraZeneca (AZ).
Dr McNamee, CSL’s Managing Director, said “All CSL divisions contributed solidly to the
Company’s excellent first half. We achieved significant profit growth despite an
environment of significant adverse currency movements.